Floatz logo

Blinatumomab

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Marlise Luskin, MDmonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

42 Active assets in the Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 2BBB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB
Imatinib
The University of Hong Kong
Phase 2BB
METHOTREXATE
University of Michigan Rogel Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →